PMC:7243768 / 27361-28298 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1072","span":{"begin":0,"end":4},"obj":"Gene"},{"id":"1073","span":{"begin":168,"end":172},"obj":"Gene"},{"id":"1074","span":{"begin":249,"end":253},"obj":"Gene"},{"id":"1075","span":{"begin":200,"end":210},"obj":"Species"},{"id":"1076","span":{"begin":455,"end":463},"obj":"Species"},{"id":"1077","span":{"begin":539,"end":547},"obj":"Species"},{"id":"1078","span":{"begin":829,"end":837},"obj":"Species"},{"id":"1079","span":{"begin":127,"end":139},"obj":"Disease"},{"id":"1080","span":{"begin":144,"end":160},"obj":"Disease"},{"id":"1081","span":{"begin":370,"end":390},"obj":"Disease"},{"id":"1082","span":{"begin":401,"end":413},"obj":"Disease"},{"id":"1083","span":{"begin":530,"end":538},"obj":"Disease"},{"id":"1084","span":{"begin":567,"end":579},"obj":"Disease"},{"id":"1085","span":{"begin":674,"end":686},"obj":"Disease"},{"id":"1086","span":{"begin":800,"end":815},"obj":"Disease"},{"id":"1087","span":{"begin":868,"end":876},"obj":"Disease"}],"attributes":[{"id":"A1072","pred":"tao:has_database_id","subj":"1072","obj":"Gene:59272"},{"id":"A1073","pred":"tao:has_database_id","subj":"1073","obj":"Gene:59272"},{"id":"A1074","pred":"tao:has_database_id","subj":"1074","obj":"Gene:59272"},{"id":"A1075","pred":"tao:has_database_id","subj":"1075","obj":"Tax:2697049"},{"id":"A1076","pred":"tao:has_database_id","subj":"1076","obj":"Tax:9606"},{"id":"A1077","pred":"tao:has_database_id","subj":"1077","obj":"Tax:9606"},{"id":"A1078","pred":"tao:has_database_id","subj":"1078","obj":"Tax:9606"},{"id":"A1079","pred":"tao:has_database_id","subj":"1079","obj":"MESH:D006973"},{"id":"A1080","pred":"tao:has_database_id","subj":"1080","obj":"MESH:D003924"},{"id":"A1081","pred":"tao:has_database_id","subj":"1081","obj":"MESH:C000657245"},{"id":"A1082","pred":"tao:has_database_id","subj":"1082","obj":"MESH:D006973"},{"id":"A1083","pred":"tao:has_database_id","subj":"1083","obj":"MESH:C000657245"},{"id":"A1084","pred":"tao:has_database_id","subj":"1084","obj":"MESH:D006973"},{"id":"A1085","pred":"tao:has_database_id","subj":"1085","obj":"MESH:D006973"},{"id":"A1086","pred":"tao:has_database_id","subj":"1086","obj":"MESH:D001102"},{"id":"A1087","pred":"tao:has_database_id","subj":"1087","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ACE2 plays a vital role in the cardiovascular system and is mainly involved in the functioning of the heart and development of hypertension and type II diabetes. Since ACE2 is the main target for the SARS-CoV-2 to enter inside the host cell and the ACE2 is also highly expressed in the heart apart from the lungs, indicating a chance of developing cardiac issues during SARS-CoV-2 infection. The anti-hypertensive therapy that has been prescribed for the patients is the usage of ACEi and ARBs should be carefully considered. The COVID-19 patients with comorbidities hypertension, taking the drug of ACEi or blocker of angiotensin receptor, need to switch off to other anti-hypertensive medications found to be controversial and require further studies this co-morbid conditions. The severity of the viral infection is higher in patients with comorbidities than those infected only by the virus without any predisposed health issue [85]."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T257","span":{"begin":31,"end":52},"obj":"Body_part"},{"id":"T258","span":{"begin":102,"end":107},"obj":"Body_part"},{"id":"T259","span":{"begin":236,"end":240},"obj":"Body_part"},{"id":"T260","span":{"begin":286,"end":291},"obj":"Body_part"},{"id":"T261","span":{"begin":307,"end":312},"obj":"Body_part"}],"attributes":[{"id":"A257","pred":"fma_id","subj":"T257","obj":"http://purl.org/sig/ont/fma/fma7161"},{"id":"A258","pred":"fma_id","subj":"T258","obj":"http://purl.org/sig/ont/fma/fma7088"},{"id":"A259","pred":"fma_id","subj":"T259","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A260","pred":"fma_id","subj":"T260","obj":"http://purl.org/sig/ont/fma/fma7088"},{"id":"A261","pred":"fma_id","subj":"T261","obj":"http://purl.org/sig/ont/fma/fma68877"}],"text":"ACE2 plays a vital role in the cardiovascular system and is mainly involved in the functioning of the heart and development of hypertension and type II diabetes. Since ACE2 is the main target for the SARS-CoV-2 to enter inside the host cell and the ACE2 is also highly expressed in the heart apart from the lungs, indicating a chance of developing cardiac issues during SARS-CoV-2 infection. The anti-hypertensive therapy that has been prescribed for the patients is the usage of ACEi and ARBs should be carefully considered. The COVID-19 patients with comorbidities hypertension, taking the drug of ACEi or blocker of angiotensin receptor, need to switch off to other anti-hypertensive medications found to be controversial and require further studies this co-morbid conditions. The severity of the viral infection is higher in patients with comorbidities than those infected only by the virus without any predisposed health issue [85]."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T126","span":{"begin":31,"end":52},"obj":"Body_part"},{"id":"T127","span":{"begin":102,"end":107},"obj":"Body_part"},{"id":"T128","span":{"begin":286,"end":291},"obj":"Body_part"}],"attributes":[{"id":"A126","pred":"uberon_id","subj":"T126","obj":"http://purl.obolibrary.org/obo/UBERON_0004535"},{"id":"A127","pred":"uberon_id","subj":"T127","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"A128","pred":"uberon_id","subj":"T128","obj":"http://purl.obolibrary.org/obo/UBERON_0000948"}],"text":"ACE2 plays a vital role in the cardiovascular system and is mainly involved in the functioning of the heart and development of hypertension and type II diabetes. Since ACE2 is the main target for the SARS-CoV-2 to enter inside the host cell and the ACE2 is also highly expressed in the heart apart from the lungs, indicating a chance of developing cardiac issues during SARS-CoV-2 infection. The anti-hypertensive therapy that has been prescribed for the patients is the usage of ACEi and ARBs should be carefully considered. The COVID-19 patients with comorbidities hypertension, taking the drug of ACEi or blocker of angiotensin receptor, need to switch off to other anti-hypertensive medications found to be controversial and require further studies this co-morbid conditions. The severity of the viral infection is higher in patients with comorbidities than those infected only by the virus without any predisposed health issue [85]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T317","span":{"begin":127,"end":139},"obj":"Disease"},{"id":"T318","span":{"begin":144,"end":160},"obj":"Disease"},{"id":"T319","span":{"begin":152,"end":160},"obj":"Disease"},{"id":"T320","span":{"begin":200,"end":208},"obj":"Disease"},{"id":"T321","span":{"begin":200,"end":204},"obj":"Disease"},{"id":"T322","span":{"begin":370,"end":378},"obj":"Disease"},{"id":"T323","span":{"begin":370,"end":374},"obj":"Disease"},{"id":"T324","span":{"begin":381,"end":390},"obj":"Disease"},{"id":"T325","span":{"begin":530,"end":538},"obj":"Disease"},{"id":"T326","span":{"begin":567,"end":579},"obj":"Disease"},{"id":"T327","span":{"begin":800,"end":815},"obj":"Disease"},{"id":"T328","span":{"begin":806,"end":815},"obj":"Disease"}],"attributes":[{"id":"A317","pred":"mondo_id","subj":"T317","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A318","pred":"mondo_id","subj":"T318","obj":"http://purl.obolibrary.org/obo/MONDO_0005148"},{"id":"A319","pred":"mondo_id","subj":"T319","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"},{"id":"A320","pred":"mondo_id","subj":"T320","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A321","pred":"mondo_id","subj":"T321","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A322","pred":"mondo_id","subj":"T322","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A323","pred":"mondo_id","subj":"T323","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A324","pred":"mondo_id","subj":"T324","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A325","pred":"mondo_id","subj":"T325","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A326","pred":"mondo_id","subj":"T326","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"},{"id":"A327","pred":"mondo_id","subj":"T327","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A328","pred":"mondo_id","subj":"T328","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"ACE2 plays a vital role in the cardiovascular system and is mainly involved in the functioning of the heart and development of hypertension and type II diabetes. Since ACE2 is the main target for the SARS-CoV-2 to enter inside the host cell and the ACE2 is also highly expressed in the heart apart from the lungs, indicating a chance of developing cardiac issues during SARS-CoV-2 infection. The anti-hypertensive therapy that has been prescribed for the patients is the usage of ACEi and ARBs should be carefully considered. The COVID-19 patients with comorbidities hypertension, taking the drug of ACEi or blocker of angiotensin receptor, need to switch off to other anti-hypertensive medications found to be controversial and require further studies this co-morbid conditions. The severity of the viral infection is higher in patients with comorbidities than those infected only by the virus without any predisposed health issue [85]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T383","span":{"begin":11,"end":12},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T384","span":{"begin":31,"end":52},"obj":"http://purl.obolibrary.org/obo/UBERON_0004535"},{"id":"T385","span":{"begin":31,"end":52},"obj":"http://www.ebi.ac.uk/efo/EFO_0000791"},{"id":"T386","span":{"begin":102,"end":107},"obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"T387","span":{"begin":102,"end":107},"obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"T388","span":{"begin":102,"end":107},"obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"T389","span":{"begin":102,"end":107},"obj":"http://www.ebi.ac.uk/efo/EFO_0000815"},{"id":"T390","span":{"begin":236,"end":240},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T391","span":{"begin":286,"end":291},"obj":"http://purl.obolibrary.org/obo/UBERON_0000948"},{"id":"T392","span":{"begin":286,"end":291},"obj":"http://purl.obolibrary.org/obo/UBERON_0007100"},{"id":"T393","span":{"begin":286,"end":291},"obj":"http://purl.obolibrary.org/obo/UBERON_0015228"},{"id":"T394","span":{"begin":286,"end":291},"obj":"http://www.ebi.ac.uk/efo/EFO_0000815"},{"id":"T395","span":{"begin":307,"end":312},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T396","span":{"begin":325,"end":326},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T397","span":{"begin":427,"end":430},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T398","span":{"begin":889,"end":894},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"ACE2 plays a vital role in the cardiovascular system and is mainly involved in the functioning of the heart and development of hypertension and type II diabetes. Since ACE2 is the main target for the SARS-CoV-2 to enter inside the host cell and the ACE2 is also highly expressed in the heart apart from the lungs, indicating a chance of developing cardiac issues during SARS-CoV-2 infection. The anti-hypertensive therapy that has been prescribed for the patients is the usage of ACEi and ARBs should be carefully considered. The COVID-19 patients with comorbidities hypertension, taking the drug of ACEi or blocker of angiotensin receptor, need to switch off to other anti-hypertensive medications found to be controversial and require further studies this co-morbid conditions. The severity of the viral infection is higher in patients with comorbidities than those infected only by the virus without any predisposed health issue [85]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T120","span":{"begin":149,"end":151},"obj":"Chemical"},{"id":"T121","span":{"begin":480,"end":484},"obj":"Chemical"},{"id":"T122","span":{"begin":592,"end":596},"obj":"Chemical"},{"id":"T123","span":{"begin":600,"end":604},"obj":"Chemical"},{"id":"T124","span":{"begin":619,"end":630},"obj":"Chemical"}],"attributes":[{"id":"A120","pred":"chebi_id","subj":"T120","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A121","pred":"chebi_id","subj":"T121","obj":"http://purl.obolibrary.org/obo/CHEBI_35457"},{"id":"A122","pred":"chebi_id","subj":"T122","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A123","pred":"chebi_id","subj":"T123","obj":"http://purl.obolibrary.org/obo/CHEBI_35457"},{"id":"A124","pred":"chebi_id","subj":"T124","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"}],"text":"ACE2 plays a vital role in the cardiovascular system and is mainly involved in the functioning of the heart and development of hypertension and type II diabetes. Since ACE2 is the main target for the SARS-CoV-2 to enter inside the host cell and the ACE2 is also highly expressed in the heart apart from the lungs, indicating a chance of developing cardiac issues during SARS-CoV-2 infection. The anti-hypertensive therapy that has been prescribed for the patients is the usage of ACEi and ARBs should be carefully considered. The COVID-19 patients with comorbidities hypertension, taking the drug of ACEi or blocker of angiotensin receptor, need to switch off to other anti-hypertensive medications found to be controversial and require further studies this co-morbid conditions. The severity of the viral infection is higher in patients with comorbidities than those infected only by the virus without any predisposed health issue [85]."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T42","span":{"begin":102,"end":123},"obj":"http://purl.obolibrary.org/obo/GO_0007507"},{"id":"T43","span":{"begin":800,"end":815},"obj":"http://purl.obolibrary.org/obo/GO_0016032"}],"text":"ACE2 plays a vital role in the cardiovascular system and is mainly involved in the functioning of the heart and development of hypertension and type II diabetes. Since ACE2 is the main target for the SARS-CoV-2 to enter inside the host cell and the ACE2 is also highly expressed in the heart apart from the lungs, indicating a chance of developing cardiac issues during SARS-CoV-2 infection. The anti-hypertensive therapy that has been prescribed for the patients is the usage of ACEi and ARBs should be carefully considered. The COVID-19 patients with comorbidities hypertension, taking the drug of ACEi or blocker of angiotensin receptor, need to switch off to other anti-hypertensive medications found to be controversial and require further studies this co-morbid conditions. The severity of the viral infection is higher in patients with comorbidities than those infected only by the virus without any predisposed health issue [85]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T186","span":{"begin":0,"end":161},"obj":"Sentence"},{"id":"T187","span":{"begin":162,"end":391},"obj":"Sentence"},{"id":"T188","span":{"begin":392,"end":525},"obj":"Sentence"},{"id":"T189","span":{"begin":526,"end":779},"obj":"Sentence"},{"id":"T190","span":{"begin":780,"end":937},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ACE2 plays a vital role in the cardiovascular system and is mainly involved in the functioning of the heart and development of hypertension and type II diabetes. Since ACE2 is the main target for the SARS-CoV-2 to enter inside the host cell and the ACE2 is also highly expressed in the heart apart from the lungs, indicating a chance of developing cardiac issues during SARS-CoV-2 infection. The anti-hypertensive therapy that has been prescribed for the patients is the usage of ACEi and ARBs should be carefully considered. The COVID-19 patients with comorbidities hypertension, taking the drug of ACEi or blocker of angiotensin receptor, need to switch off to other anti-hypertensive medications found to be controversial and require further studies this co-morbid conditions. The severity of the viral infection is higher in patients with comorbidities than those infected only by the virus without any predisposed health issue [85]."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T138","span":{"begin":127,"end":139},"obj":"Phenotype"},{"id":"T139","span":{"begin":144,"end":160},"obj":"Phenotype"},{"id":"T140","span":{"begin":567,"end":579},"obj":"Phenotype"},{"id":"T141","span":{"begin":784,"end":815},"obj":"Phenotype"}],"attributes":[{"id":"A138","pred":"hp_id","subj":"T138","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A139","pred":"hp_id","subj":"T139","obj":"http://purl.obolibrary.org/obo/HP_0005978"},{"id":"A140","pred":"hp_id","subj":"T140","obj":"http://purl.obolibrary.org/obo/HP_0000822"},{"id":"A141","pred":"hp_id","subj":"T141","obj":"http://purl.obolibrary.org/obo/HP_0031691"}],"text":"ACE2 plays a vital role in the cardiovascular system and is mainly involved in the functioning of the heart and development of hypertension and type II diabetes. Since ACE2 is the main target for the SARS-CoV-2 to enter inside the host cell and the ACE2 is also highly expressed in the heart apart from the lungs, indicating a chance of developing cardiac issues during SARS-CoV-2 infection. The anti-hypertensive therapy that has been prescribed for the patients is the usage of ACEi and ARBs should be carefully considered. The COVID-19 patients with comorbidities hypertension, taking the drug of ACEi or blocker of angiotensin receptor, need to switch off to other anti-hypertensive medications found to be controversial and require further studies this co-morbid conditions. The severity of the viral infection is higher in patients with comorbidities than those infected only by the virus without any predisposed health issue [85]."}

{"project":"2_test","denotations":[{"id":"32450165-32231330-66451073","span":{"begin":933,"end":935},"obj":"32231330"}],"text":"ACE2 plays a vital role in the cardiovascular system and is mainly involved in the functioning of the heart and development of hypertension and type II diabetes. Since ACE2 is the main target for the SARS-CoV-2 to enter inside the host cell and the ACE2 is also highly expressed in the heart apart from the lungs, indicating a chance of developing cardiac issues during SARS-CoV-2 infection. The anti-hypertensive therapy that has been prescribed for the patients is the usage of ACEi and ARBs should be carefully considered. The COVID-19 patients with comorbidities hypertension, taking the drug of ACEi or blocker of angiotensin receptor, need to switch off to other anti-hypertensive medications found to be controversial and require further studies this co-morbid conditions. The severity of the viral infection is higher in patients with comorbidities than those infected only by the virus without any predisposed health issue [85]."}